Drug Profile
RBM 002
Alternative Names: RBM002Latest Information Update: 23 May 2019
Price :
$50
*
At a glance
- Originator Ribomic
- Class Peptide aptamers
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Fibrosis; Haematological disorders
Most Recent Events
- 23 May 2019 No development reported - Preclinical for Fibrosis in Japan (unspecified route)
- 23 May 2019 No development reported - Preclinical for Haematological disorders in Japan (unspecified route)
- 21 Jul 2016 Preclinical trials in Fibrosis in Japan (unspecified route)